NCT01630967View on ClinicalTrials.gov

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Prostate Neoplasm
Interventions
DRUG

Degarelix

Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.

Trial Locations (1)

V5Z4E6

British Columbia Cancer Agency, Vancouver

Sponsors

Collaborators (1)

Ferring Pharmaceuticals
All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

British Columbia Cancer Agency

OTHER

NCT01630967 - Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC) | Biotech Hunter | Biotech Hunter